

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

	Child				Adult			
	FY25		FY26		FY25		FY26	
<u>Vaccine Cost Estimates</u>								
Estimated Non-Flu Vaccine Cost Based on Current CDC Prices		\$ 17,732,728		\$ 19,208,440		\$ 11,429,417		\$ 14,742,630
Estimated Flu Vaccine Cost Based on Current CDC Prices		\$ 924,831		\$ 938,332		\$ 8,957,604		\$ 8,128,411
Estimated COVID-19 Vaccine Cost Based on Current CDC Prices		\$ 2,205,245		\$ 2,000,278		\$ 13,220,600		\$ 7,195,166
Total Estimated Vaccine Cost Based on Current CDC Prices		\$ 20,862,804		\$ 22,147,050		\$ 33,607,621		\$ 30,066,207
Provision for Vaccine Cost Increase	1.1%	\$ 225,427	0.3%	\$ 69,274	4.1%	\$ 1,380,187	4.1%	\$ 1,229,797
Subtotal Estimated Vaccine Costs		\$ 21,088,231		\$ 22,216,324		\$ 34,987,807		\$ 31,296,004
Total Estimated Vaccine Costs		\$ 21,088,231		\$ 22,216,324		\$ 34,987,807		\$ 31,296,004
Total Administrative and Operating Costs		\$ 4,504,896		\$ 6,025,369		\$ 5,236,911		\$ 7,303,904
Total Reserves / Working Capital		\$ (1,854,101)		\$ (2,363,657)		\$ (6,310,595)		\$ (4,776,713)
Total Assessable Covered Lives Estimate		85,424		85,831		560,883		529,436
<u>Assessment Calculation</u>								
Total Assessment		\$ 23,739,026		\$ 25,878,035		\$ 33,914,123		\$ 33,823,195
Total Assessment Per Covered Life		\$ 277.90		\$ 301.50		\$ 60.47		\$ 63.89
Monthly Assessment Per Covered Life Calculated / % Change		\$ 23.16	8.5%	\$ 25.13		\$ 5.04	5.7%	\$ 5.32
<u>Preliminary Projection</u>								
Run Rate Monthly Assessment Per Covered Life		\$ 24.97		\$ 27.42		\$ 5.98		\$ 6.08
Excess Reserves Applied		\$ -		\$ (1.79)		\$ -		\$ (0.71)
Preliminary Assessment Projection	1.1%	\$ 25.24	0.3%	\$ 25.72	4.1%	\$ 6.22	4.1%	\$ 5.61
Preliminary Assessment Increase		8.98%		2.37%		23.48%		5.37%
<u>Program Metrics</u>								
Administrative and Operational Costs as % of Vaccine Costs		21.36%		27.12%		14.97%		23.34%
CDC Vaccine Costs as % Below Private Purchase Costs		-27.30%		-28.20%		-29.79%		-38.65%

Notes:

Target Reserve balance is equal to 3 months of operating costs (vaccines + administrative and operational costs) -- about \$14 million

Reserves at the current year-end are estimated to exceed the target reserve balance by about \$13 million

This assessment calculation assumes that 50% of the excess reserves have been applied to reduce the FY2026 assessment rate, which will maintain rate stability through FY2027

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

Change in Assessment (Fiscal Year Ending June 30, 2025 to Fiscal Year Ending June 30, 2026)

	Child			Adult		
	Cost	PMPM	% Change	Cost	PMPM	% Change
2025 Fiscal Year Ending June 30, 2025	\$23,739,026	\$ 23.16		\$33,914,123	\$ 5.04	
Change In:						
Contribution Enrollees		\$ (0.11)	-0.5%		\$ 0.30	6.0%
Estimated Vaccine Cost	\$ 1,284,246	\$ 1.25	5.4%	\$ (3,541,414)	\$ (0.56)	-11.1%
Provision For Vaccine Cost Increase	\$ (156,153)	\$ (0.15)	-0.6%	\$ (150,390)	\$ (0.02)	-0.4%
Administrative Costs	\$ 1,263,319	\$ 1.23	5.3%	\$ 1,422,717	\$ 0.22	4.4%
Operational Costs	\$ 257,154	\$ 0.25	1.1%	\$ 644,277	\$ 0.10	2.0%
Reserve/Working Capital	\$ (509,557)	\$ (0.49)	-2.1%	\$ 1,533,882	\$ 0.24	4.8%
2026 Fiscal Year Ending June 30, 2026	\$25,878,035	\$ 25.13	8.5%	\$33,823,195	\$ 5.32	5.7%

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

CDC vaccine costs are 35% lower than private purchase costs (overall, child & adult).

Top 10 Vaccines - Child

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	\$ Savings Per Dose
HPV – Human Papillomavirus 9-valent F	Gardasil®9	00006-4121-02	20,000	\$ 257.07	\$ 5,141,420	23%	\$ 307.61	\$ 6,152,200	\$ 50.54
Pneumococcal	Prevnam 20TM	00005-2000-10	10,750	\$ 192.46	\$ 2,068,945	9%	\$ 274.60	\$ 2,951,950	\$ 82.14
DTaP-IPV-HIB-HEPB E	Vaxelis™	63361-0243-15	15,800	\$ 103.76	\$ 1,639,408	7%	\$ 156.70	\$ 2,475,860	\$ 52.94
Meningococcal Conjugate (Groups A, C, W and Y) F	MenQuadfi™	49281-0590-10	13,500	\$ 114.36	\$ 1,543,860	7%	\$ 171.97	\$ 2,321,622	\$ 57.61
MENB – Meningococcal Group B F	Bexsero®	58160-0976-20	8,800	\$ 154.50	\$ 1,359,635	6%	\$ 237.13	\$ 2,086,709	\$ 82.62
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0575-15	3,000	\$ 414.75	\$ 1,244,250	6%	\$ 556.13	\$ 1,668,396	\$ 141.38
MMR/Varicella C	ProQuad®	00006-4171-00	6,550	\$ 186.55	\$ 1,221,903	6%	\$ 278.16	\$ 1,821,961	\$ 91.61
Rotavirus, Live, Oral, Oral F	Rotarix®	58160-0740-21	10,900	\$ 111.72	\$ 1,217,770	5%	\$ 147.02	\$ 1,602,518	\$ 35.30
Varicella F	Varivax®	00006-4827-00	6,880	\$ 151.45	\$ 1,041,948	5%	\$ 183.00	\$ 1,259,054	\$ 31.56
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0574-15	2,500	\$ 414.75	\$ 1,036,875	5%	\$ 556.13	\$ 1,390,330	\$ 141.38

Top 10 Vaccines - Adult

Vaccine	Brandname/ Tradename	NDC	Dose Quantity	CDC Cost/ Dose	Projected Vaccine Cost	% of Total	Private Sector Cost/ Dose	Projected Private Cost	\$ Savings Per Dose
Pneumococcal	Prevnam 20™	00005-2000-10	40,000	\$ 178.57	\$ 7,499,940	24%	\$ 274.60	\$ 11,533,200	\$ 100.83
Covid-19 (Age 12 years and older)	Spikevax™	80777-0110-93	50,000	\$ 78.28	\$ 4,109,700	13%	\$ 141.80	\$ 7,444,500	\$ 66.70
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2432-10	45,000	\$ 69.44	\$ 3,281,040	10%	\$ 136.75	\$ 6,461,438	\$ 70.68
Influenza F	Fluzone® High-dose TIV	49281-0125-65	50,000	\$ 56.45	\$ 2,868,854	9%	\$ 75.54	\$ 3,838,808	\$ 19.40
Influenza F	Fluad TIV	70461-0025-03	50,000	\$ 56.41	\$ 2,866,364	9%	\$ 73.36	\$ 3,728,077	\$ 17.23
Zoster Vaccine Recombinant, Adjuvanted	Shingrix®	58160-0823-11	15,000	\$ 124.56	\$ 1,961,789	6%	\$ 215.51	\$ 3,394,251	\$ 95.50
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular	Adacel®	49281-0400-20	58,000	\$ 28.49	\$ 1,735,041	6%	\$ 49.20	\$ 2,996,280	\$ 21.75
Influenza F	Flucelvax® TIV	70461-0655-03	70,000	\$ 20.43	\$ 1,453,128	5%	\$ 32.45	\$ 2,308,499	\$ 12.22
Influenza F	Fluzone®	49281-0425-50	73,620	\$ 14.34	\$ 1,072,973	3%	\$ 20.88	\$ 1,562,170	\$ 6.64
HPV-Human Papillomavirus 9 Valent F	Gardasil®9	00006-4121-02	4,800	\$ 182.79	\$ 921,267	3%	\$ 307.61	\$ 1,550,354	\$ 131.06

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

Reserve Scenario Comparison

Excess Cash Release %	2026 Fiscal Year Assessment Rates		2027 Fiscal Year Assessment Rates*	
	Child	Adult	Child	Adult
0%	\$ 27.18	\$ 6.15	\$ 24.20	\$ 5.01
25%	\$ 26.15	\$ 5.73	\$ 24.96	\$ 5.31
50%	\$ 25.13	\$ 5.32	\$ 25.72	\$ 5.61
75%	\$ 24.10	\$ 4.91	\$ 26.48	\$ 5.91
100%	\$ 23.07	\$ 4.50	\$ 27.24	\$ 6.21

**Assumes unused reserves from current year will be applied in subsequent year.*

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

Comparison to Prior Period

		Cost Per Dose	Doses	Cost
Total Pediatric	Prior Period Projected	\$ 85.45	246,795	\$ 21,088,231
	Current Period Projected	\$ 90.56	245,320	\$ 22,216,324
	Variance	\$ 5.11	-1,475	\$ 1,128,093
	% Variance	6.0%	-0.6%	5.3%
Total Adult	Prior Period Projected	\$ 63.74	548,910	\$ 34,987,807
	Current Period Projected	\$ 62.51	500,660	\$ 31,296,004
	Variance	\$ (1.23)	-48,250	\$ (3,691,804)
	% Variance	-1.9%	-8.8%	-10.6%
Pediatric	Prior Period Projected	\$ 112.60	158,655	\$ 17,864,253
	Current Period Projected	\$ 119.17	161,180	\$ 19,208,440
	Variance	\$ 6.58	2,525	\$ 1,344,187
	% Variance	5.8%	1.6%	7.5%
Adult	Prior Period Projected	\$ 88.37	135,800	\$ 12,000,888
	Current Period Projected	\$ 97.04	159,520	\$ 15,479,761
	Variance	\$ 8.67	23,720	\$ 3,478,873
	% Variance	9.8%	17.5%	29.0%
Pediatric Flu	Prior Period Projected	\$ 16.28	58,510	\$ 952,576
	Current Period Projected	\$ 16.20	58,510	\$ 947,597
	Variance	\$ (0.09)	0	\$ (4,978)
	% Variance	-0.5%	0.0%	-0.5%
Adult Flu	Prior Period Projected	\$ 35.97	253,110	\$ 9,105,289
	Current Period Projected	\$ 33.91	243,620	\$ 8,261,318
	Variance	\$ (2.06)	-9,490	\$ (843,971)
	% Variance	-5.7%	-3.7%	-9.3%
Pediatric COVID-19	Prior Period Projected	\$ 76.66	29,630	\$ 2,271,402
	Current Period Projected	\$ 80.39	25,630	\$ 2,060,286
	Variance	\$ 3.73	-4,000	\$ (211,116)
	% Variance	4.9%	-13.5%	-9.3%
Adult COVID-19	Prior Period Projected	\$ 86.76	160,000	\$ 13,881,630
	Current Period Projected	\$ 77.47	97,520	\$ 7,554,924
	Variance	\$ (9.29)	-62,480	\$ (6,326,706)
	% Variance	-10.7%	-39.1%	-45.6%

Rhode Island Fiscal Year Ending June 30, 2026 Assessment

Summary Statistics

	Current Assessment Period									
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Projected Vaccine Cost
Total Pediatric	245,320	\$ 22,147,050	\$ 30,846,812	\$ 30,946,594	\$ -	0.3%	\$ 69,274	0.0%	\$ -	\$ 22,216,324
Total Adult	500,660	\$ 30,066,207	\$ 49,006,546	\$ 51,078,202	\$ -	4.1%	\$ 1,229,797	0.0%	\$ -	\$ 31,296,004
Pediatric	161,180	\$ 19,208,440	\$ 26,671,685	\$ 26,671,685	\$ -	0.0%	\$ -	0.0%	\$ -	\$ 19,208,440
Adult	159,520	\$ 14,742,630	\$ 24,152,163	\$ 25,359,771	\$ -	5.0%	\$ 737,131	0.0%	\$ -	\$ 15,479,761
Pediatric Flu	58,510	\$ 938,332	\$ 1,265,666	\$ 1,278,163	\$ -	1.0%	\$ 9,265	0.0%	\$ -	\$ 947,597
Adult Flu	243,620	\$ 8,128,411	\$ 11,253,548	\$ 11,437,555	\$ -	1.6%	\$ 132,907	0.0%	\$ -	\$ 8,261,318
Pediatric COVID-19	25,630	\$ 2,000,278	\$ 2,909,462	\$ 2,996,746	\$ -	3.0%	\$ 60,008	0.0%	\$ -	\$ 2,060,286
Adult COVID-19	97,520	\$ 7,195,166	\$ 13,600,834	\$ 14,280,876	\$ -	5.0%	\$ 359,758	0.0%	\$ -	\$ 7,554,924

	Prior Assessment Period									
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Projected Vaccine Cost
Total Pediatric	246,795	\$ 20,862,804	\$ 28,697,393	\$ 29,005,491	\$ -	1.1%	\$ 225,427	0.0%	\$ -	\$ 21,088,231
Total Adult	548,910	\$ 33,607,621	\$ 47,868,068	\$ 49,916,386	\$ -	4.1%	\$ 1,380,187	0.0%	\$ -	\$ 34,987,807
Pediatric	158,655	\$ 17,732,728	\$ 24,479,722	\$ 24,661,290	\$ -	0.7%	\$ 131,525	0.0%	\$ -	\$ 17,864,253
Adult	135,800	\$ 11,429,417	\$ 17,955,959	\$ 18,853,757	\$ -	5.0%	\$ 571,471	0.0%	\$ -	\$ 12,000,888
Pediatric Flu	58,510	\$ 924,831	\$ 1,238,271	\$ 1,275,419	\$ -	3.0%	\$ 27,745	0.0%	\$ -	\$ 952,576
Adult Flu	253,110	\$ 8,957,604	\$ 10,297,108	\$ 10,466,879	\$ -	1.6%	\$ 147,686	0.0%	\$ -	\$ 9,105,289
Pediatric COVID-19	29,630	\$ 2,205,245	\$ 2,979,400	\$ 3,068,782	\$ -	3.0%	\$ 66,157	0.0%	\$ -	\$ 2,271,402
Adult COVID-19	160,000	\$ 13,220,600	\$ 19,615,000	\$ 20,595,750	\$ -	5.0%	\$ 661,030	0.0%	\$ -	\$ 13,881,630

	CDC Cost to Private Cost %	Difference Between CDC Cost/ Dose and Private Cost/ Dose	Cost Change Due to Price Change	% Change in Cost/ Dose	Change in Dose Quantity	Cost at Prior Year Dose Quantity	Cost Change Due to Dose Change	% Cost Change Due to Dose Change	Total Cost Change
Total Pediatric	-28.2%	\$ (2,094.03)	\$ 830,161	4.0%	(1,475)	\$ 21,692,965	\$ 454,085	2.1%	\$ 1,284,246
Total Adult	-38.6%	\$ (2,175.52)	\$ (1,981,445)	-5.9%	(48,250)	\$ 31,626,176	\$ (1,559,969)	-4.9%	\$ (3,541,414)
Pediatric	-28.0%	\$ (1,765.84)	\$ 809,273	4.6%	2,525	\$ 18,542,002	\$ 666,438	3.6%	\$ 1,475,712
Adult	-39.0%	\$ (1,860.15)	\$ 120,782	1.1%	23,720	\$ 11,550,199	\$ 3,192,431	27.6%	\$ 3,313,213
Pediatric Flu	-25.9%	\$ (92.35)	\$ 13,501	1.5%	-	\$ 938,332	\$ -	0.0%	\$ 13,501
Adult Flu	-27.8%	\$ (104.89)	\$ (765,457)	-8.5%	(9,490)	\$ 8,192,147	\$ (63,736)	-0.8%	\$ (829,193)
Pediatric COVID-19	-31.2%	\$ (235.84)	\$ 7,387	0.3%	(4,000)	\$ 2,212,632	\$ (212,353)	-9.6%	\$ (204,967)
Adult COVID-19	-47.1%	\$ (210.48)	\$ (1,336,770)	-10.1%	(62,480)	\$ 11,883,830	\$ (4,688,664)	-39.5%	\$ (6,025,434)